Analyst consensus rating
Tandem Diabetes Care Analyst Rating: Buy
TNDM is rated Buy by 20 analysts with a $28.70 target. As of 2026-09-01.
Direct answer
Tandem Diabetes Care's consensus rating is Buy.
20 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $28.70.
Forecast evidence checked September 1, 2026.
Get free Tandem Diabetes Care email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $22.01
- Average price target
- $28.70
- High price target
- $50.00
- Low price target
- $18.00
- Low target gap
- -18.2%
- Target upside
- +30.4%
- High target gap
- +127.2%
- Target range width
- 145.4%
- Consensus rating
- Buy
- Analysts
- 20
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Tandem Diabetes Care?
Tandem Diabetes Care has a verified Buy consensus. The same dataset has an average price target of $28.70.
How far are Tandem Diabetes Care's low and high targets from the recorded price?
The low target implies -18.2%, while the high target implies +127.2%.
How many analysts are included in Tandem Diabetes Care's consensus?
The verified consensus includes 20 analysts.
How is Tandem Diabetes Care's target upside or downside calculated?
The average target of $28.70 is divided by the recorded price of $22.01, then one is subtracted to produce +30.4%. This does not guarantee a future return.
When was Tandem Diabetes Care's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.